Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
335
2012 to 2026
Breakthrough
335
Accelerated
74
Priority review
316
Orphan
234
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2012 | 0 | 0 |
| 2013 | 2 | 1 |
| 2014 | 10 | 4 |
| 2015 | 10 | 10 |
| 2016 | 11 | 10 |
| 2017 | 19 | 11 |
| 2018 | 20 | 18 |
| 2019 | 16 | 9 |
| 2020 | 20 | 11 |
| 2021 | 21 | 9 |
| 2022 | 13 | 13 |
| 2023 | 9 | 8 |
| 2024 | 18 | 12 |
| 2025 | 23 | 12 |
| 2026 | 8 | 7 |
335 approvals
Newest first. Hover a badge for what it means.
- Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
To treat thyroid eye disease
- Ibrance (Palbociclib) · PfizerJun 24, 2026
- Ibrance (Palbociclib) · PfizerJun 24, 2026
- Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCJun 24, 2026
- Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
- Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) · Daiichi SankyoMay 15, 2026
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V.May 8, 2026
- Auvelity (Bupropion Hydrochloride, Dextromethorphan Hydrobromide) · AxsomeApr 30, 2026
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Imcivree (Setmelanotide Acetate) · RhythmMar 19, 2026
- Tecvayli (Teclistamab-Cqyv) · Janssen BiotechMar 5, 2026
- Hernexeos (Zongertinib) · Boehringer IngelheimFeb 26, 2026
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
To treat Menkes disease
- Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- Jascayd (Nerandomilast) · Boehringer IngelheimDec 19, 2025
- Myqorzo (Aficamten) · CytokineticsDec 19, 2025
To treat symptomatic obstructive hypertrophic cardiomyopathy
- Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) · Daiichi SankyoDec 15, 2025
- Imfinzi (Durvalumab) · Astrazeneca Uk LTDNov 25, 2025
- Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
- Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
- Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Epkinly (Epcoritamab-Bysp) · Genmab US, Inc.Nov 18, 2025
- Komzifti (Ziftomenib) · KuraNov 13, 2025
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
- Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
- Gazyva (Obinutuzumab) · GenentechOct 17, 2025
- Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
To treat idiopathic pulmonary fibrosis
- Evkeeza (Evinacumab-Dgnb) · Regeneron PharmaceuticalsSep 25, 2025
- Inlexzo (Gemcitabine Hydrochloride) · Janssen BiotechSep 9, 2025
- Wegovy (Semaglutide) · NovoAug 15, 2025
- Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
To treat non-cystic fibrosis bronchiectasis
- Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
- Zegfrovy (Sunvozertinib) · DizalJul 2, 2025Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy
- Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
- Yeztugo (Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
- Yeztugo (Lenacapavir, Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
- Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
- Mavyret (Glecaprevir, Pibrentasvir) · AbbvieJun 10, 2025
- Mavyret (Glecaprevir, Pibrentasvir) · AbbvieJun 10, 2025
- Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy
- Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
- Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
- Uplizna (Inebilizumab-Cdon) · Viela BioApr 3, 2025
- Vykat Xr (Diazoxide Choline) · SolenoMar 26, 2025
- Fabhalta (Iptacopan Hydrochloride) · NovartisMar 20, 2025
- Journavx (Suzetrigine) · Vertex Pharms INCJan 30, 2025
To treat moderate to severe acute pain
- Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) · Daiichi SankyoJan 27, 2025
- Spravato (Esketamine Hydrochloride) · Janssen PharmsJan 17, 2025
- Lumakras (Sotorasib) · Amgen INCJan 16, 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.